Trial Profile

A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 21 Feb 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary) ; Gemcitabine; Oxaliplatin
Indications Biliary cancer
Focus Adverse reactions

Most Recent Events

14 Feb 2018 Status changed from suspended to withdrawn prior to enrolment.
06 Jul 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017, as reported by ClinicalTrials.gov.
06 Jul 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com